* Talks were selected from submitted Abstracts


15:00 – 21:00      Registration open

18:00 – 21:00      Opening ceremony/cocktail reception (semi-casual – food will be served)


07:00 – 08:10    Breakfast

08:00 – 08:15    Welcoming Address

08:15 – 09:15     Keynote lecture

  • Sandra Black MA MD, University of Toronto (Clinical, imaging and pathological heterogeneity of Alzheimer’s disease)

09:15 – 10:15      Plenary Session 1

  • John Breitner MD MPH, McGill University (The road to Alzheimer’s disease prevention)
  • Gerhard Multhaup PhD, McGill University (Linking amyloid and APLPs in Alzheimer’s disease)

10:15 – 10:45      Coffee break

10:45 – 12:45       Focused Session on (1) Amyloid, (2) AD models, (3) Genetics

  • Georges Levesque PhD, Université Laval (Innovative approach to decrease cellular amyloid)
  • Lisa-Marie Münter PhD, McGill University (Rhomboid-related protease-4 cleaves the amyloid precursor protein)
  • Jonathan Brouillette PhD, Université de Montréal (The effect of Aβ oligomers and tyrosine phosphatase STEP in Alzheimer’s disease and mild cognitive impairment)
  • *William Gendron, Dalhousie University (Age-related changes in feeding behaviour, activity, body composition, and metabolic hormones in female 5xFAD mice)
  • *Matthew Granger, University of Ottawa (Sex differences in learning and memory in the TgCRND8 mouse model of Alzheimer’s disease)
  • *Justin Miron, McGill University (Analysis of genetic factors in the common form of Alzheimer’s disease)
  • *Cynthia Picard, McGill University (Genome-wide association study using Alzheimer-related pathological biomarkers)

12:45 – 13:45      Lunch

13:45 – 15:45      Plenary Session 2

  • Serge Gauthier MD FRCPC, McGill University (Challenges in translating animal models-based treatment hypothesis in clinical trials)
  • Steffany Bennett PhD, University of Ottawa (Aberrant glycerophosphocholine metabolism is a primary and targetable pathology in Alzheimer’s disease)
  • Serge Rivest PhD, Université Laval (Protecting your brain with innate immune cells)
  • Nicole D. Anderson PhD, University of Toronto (Cognitive interventions for mild cognitive impairment)

15:45 – 18:30     Poster session + Social (wine & cheese)

18:30                    On your own for dinner


07:00 – 08:00      Breakfast

08:00 – 9:30        Plenary Session 3

  • Cheryl Wellington PhD, University of British Columbia (From concussion to dementia)
  • David Vocadlo PhD, Simon Fraser University (Cytoplasmic O-glycosylation as a target for disease modifying therapy in Alzheimer’s)
  • Andrea C. LeBlanc PhD, McGill University (Caspase activity and cognitive decline in Alzheimer’s disease)

9:30 – 10:00        Coffee Break

10:00 – 12:00      Focused Session on (4) Tau, (5) Neuroinflammation, and (6) Neurovascular

  • Nicole Leclerc PhD, Université de Montréal (Starvation and inhibition of lysosome function increased tau secretion by primary cortical neurons)
  • Emmanuel Planel PhD, Université Laval (Huntington’s disease is a tauopathy: mutant huntingtin induces tau hyperphosphorylation though inhibition of calcineurin)
  • Karen E. Duff PhD, Columbia University (The propagation of tau pathology)
  • *Daniel Felsky, University of Toronto (Translocator Protein (18kDa) rs6971 is associated with markers of cerebrovascular disease and neuroinflammation)
  • *Jessika Royea, McGill University (Insulin regulated aminopeptidase (IRAP) as a potential cerebrovascular and neuroprotective mechanism in a mouse model of Alzheimer’s disease)
  • *Aaron Y. Lai PhD, University of Toronto (Unexpected role of venular degeneration in the development of cerebral amyloid angiopathy)
  • *Wael Alata PhD, Université Laval (Cerebral glucose transport and blood-brain barrier morphology are altered in function of Apolipoprotein E genotype in mice)

12:00 – 13:00      Lunch

13:00 – 14:00      Keynote lecture

14:15 – 16:15      Focused Session on (7) Neuroimaging, (8) Prevention and Treatments, and (9) Comorbidity and Other aetiologies

  • Simon Duchesne PhD, Université Laval (Harmonized hippocampal segmentation: a standardized biomarker)
  • Robert Jr Laforce MD PhD FRCPC, Université Laval (Role of PET imaging in the differential diagnosis of complex/atypical dementia)
  • Eddy Larouche, Université Laval (Could meditation delay or prevent cognitive decline?)
  • Frederic Calon PhD, Université Laval (The many ways to lower Alzheimer’s disease neuropathology: lessons from preclinical studies)
  • *Marie-Elyse Lafaille-Magnan, McGill University (Olfactory identification helps predict CSF t-tau/Aβ42 concentration in cognitively normal adults
  • *Alanna McEneny, University of Waterloo (Chemical structure modification of tacrine and its effects on CYP1A2 binding: in vitro and in silico investigations)
  • *SaiSampath Thammisetty, Université Laval (Age-dependent cytoplasmic TDP-43 accumulation in cerebral ischemia)

16:15                     Closing remarks

16:20                    Departure